This article is more than 5 years old. Information may no longer be current.
Crespine Gel may reduce pain in patients with knee OA
Click Here to Manage Email Alerts
Patients with knee osteoarthritis who received intra-articular injections of Crespine Gel, a hyaluronic acid solution, had improvements in pain, stiffness and physical function at 9 months of follow-up, according to recently published research.
A cohort of 84 patients with osteoarthritis (OA) who underwent injections of Crespine Gel (hyaluronic acid, Opto-Hellas) and completed nine follow-up visits were included in a prospective, non-randomized, non-blinded, phase 4, multicenter, postmarketing trial. Patients were mostly male (63.64%) and of Middle Eastern descent. Comorbidities such as cardiovascular disease, diabetes and hypertension were prevalent, and patients’ mean BMI was 30.5. Patients were excluded in the presence of other inflammatory joint disease, psoriatic arthritis, prior knee fracture, known allergies related to the procedure, renal dysfunction or malignancy.
Four physicians from different regions of Jordan were involved with the study and used identical case reporting methods.
Prior to injection, patients were screened for OA based on the Kellgren-Lawrence scale and radiographic examination. Additionally, the patients were assessed at each follow-up visit by calculating the WOMAC score.
Hyaluronic acid was injected laterally into each affected knee, and a safety evaluation was conducted 72 hours later, during which patients were questioned about pain at the injection site. Of the 84 patients, 33 reported increased pain, seven of whom had redness; five patients had pain and swelling, and four had pain, swelling and redness. Patients with pain had reduced mobility, which subsided after 2 to 3 days, according to the researchers.
Knee pain was assessed at 3, 6 and 9 months, and 99% of the patients showed at least a 20% response. Of those, 75% were 70% responders, and 82% responded by 50% or greater. Peak improvement was seen at 5 months, according to the researchers. - by Shirley Pulawski
Disclosure: The corresponding author reports a business relationship exists with the funding organization but that no other conflicts are present with the other authors.
Click Here to Manage Email Alerts